更正：杜氏肌营养不良症可步行患者中，具有适合跳跃外显子44、45、51和53的突变的长期自然史数据。
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
作者信息
Brogna Claudia, Coratt Giorgia, Pane Marika, Ricotti Valeria, Messina Sonia, D'Amico Adele, Bruno Claudio, Vita Gianluca, Berardinelli Angela, Mazzone Elena, Magri Francesca, Ricci Federica, Mongini Tiziana, Battini Roberta, Bello Luca, Pegoraro Elena, Baranello Giovanni, Previtali Stefano C, Politano Luisa, Comi Giacomo P, Sansone Valeria A, Donati Alice, Bertini Enrico, Muntoni Francesco, Goemans Nathalie, Mercuri Eugenio
出版信息
PLoS One. 2019 Jul 31;14(7):e0220714. doi: 10.1371/journal.pone.0220714. eCollection 2019.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0218683.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0218683。]
相似文献
1
Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
PLoS One. 2019 Jul 31;14(7):e0220714. doi: 10.1371/journal.pone.0220714. eCollection 2019.
2
Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
PLoS One. 2016 Jul 19;11(7):e0159895. doi: 10.1371/journal.pone.0159895. eCollection 2016.
3
Correction: Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
PLoS One. 2019 Feb 20;14(2):e0212820. doi: 10.1371/journal.pone.0212820. eCollection 2019.
4
Correction: Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
PLoS One. 2020 Jul 23;15(7):e0236916. doi: 10.1371/journal.pone.0236916. eCollection 2020.
5
Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy.
PLoS One. 2018 Nov 15;13(11):e0207817. doi: 10.1371/journal.pone.0207817. eCollection 2018.
6
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x.
7
Correction: Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.
PLoS One. 2015 Mar 25;10(3):e0121882. doi: 10.1371/journal.pone.0121882. eCollection 2015.
8
Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes.
PLoS One. 2015 Dec 4;10(12):e0144079. doi: 10.1371/journal.pone.0144079. eCollection 2015.
9
Correction: Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
PLoS One. 2020 Oct 22;15(10):e0241430. doi: 10.1371/journal.pone.0241430. eCollection 2020.
10
A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD).
Hum Gene Ther Clin Dev. 2015 Jun;26(2):92-5. doi: 10.1089/humc.2015.2528.
引用本文的文献
1
The Dutch Dystrophinopathy Database: A National Registry with Standardized Patient and Clinician Reported Real-World Data.
J Neuromuscul Dis. 2024;11(5):1095-1109. doi: 10.3233/JND-240061.
2
Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials.
Neurology. 2023 Apr 11;100(15):e1540-e1554. doi: 10.1212/WNL.0000000000201626. Epub 2023 Feb 1.
3
Clinical and Genetic Characteristics in Young, Glucocorticoid-Naive Boys With Duchenne Muscular Dystrophy.
Neurology. 2022 Jan 24;98(4):e390-e401. doi: 10.1212/WNL.0000000000013122.
本文引用的文献
1
Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.
PLoS One. 2019 Jun 25;14(6):e0218683. doi: 10.1371/journal.pone.0218683. eCollection 2019.
Zotero 插件